Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice

Research output: Contribution to journalArticlepeer-review


Background: In addition to the treatment of specific cardiovascular risk factors, intervention which interferes with the general mechanisms of atherosclerosis could further reduce the incidence of cardiovascular events. We aimed to investigate in general practice the efficacy of antiplatelets and antioxidants in primary prevention of cardiovascular events in people with one or more major cardiovascular risk factors. Methods: We did a randomised controlled open 2×2 factorial trial to investigate low-dose aspirin (100 mg/day) and vitamin E (300 mg/day) in the prevention of cardiovascular events, in people with one or more of the following: hypertension, hypercholesterolaemia, diabetes, obesity, family history of premature myocardial infarction, or individuals who were elderly. Findings: 4495 people (2583 female, mean age 64-4 years) were included in the trial. After a mean follow-up of 3-6 years the trial was prematurely stopped on ethical grounds when newly available evidence from other trials on the benefit of aspirin in primary prevention was strictly consistent with the results of the second planned interim analysis. Aspirin lowered the frequency of all the endpoints, being significant for cardiovascular death (from 1.4 to 0.8%; relative risk 0.56 [95% Cl 0.31-0.99]) and total cardiovascular events (from 8.2 to 6.3%; 0.77 [0.62-0.95]). Severe bleedings were more frequent in the aspirin group than the no-aspirin group (1.1% vs 0.3%: p

Original languageEnglish
Pages (from-to)89-95
Number of pages7
Issue number9250
Publication statusPublished - Jan 13 2001

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice'. Together they form a unique fingerprint.

Cite this